[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  SEC Filings Digest [@USCorpFilings](/creator/twitter/USCorpFilings) on x 4253 followers Created: 2025-07-07 12:30:08 UTC $DNLI Clinical Trials: On July 7, 2025, Denali Therapeutics announced that the U.S. FDA accepted its Biologics License Application for tividenofusp alfa to treat Hunter syndrome, granting it Priority Review. XXX engagements  **Related Topics** [sec](/topic/sec) [$dnli](/topic/$dnli) [Post Link](https://x.com/USCorpFilings/status/1942199453030776924)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
SEC Filings Digest @USCorpFilings on x 4253 followers
Created: 2025-07-07 12:30:08 UTC
$DNLI Clinical Trials:
On July 7, 2025, Denali Therapeutics announced that the U.S. FDA accepted its Biologics License Application for tividenofusp alfa to treat Hunter syndrome, granting it Priority Review.
XXX engagements
/post/tweet::1942199453030776924